The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
J. Wilson, Amir Nikooienejad, D. Robins, W. Roell, J. Riesmeyer, A. Haupt, K. Duffin, M. Taskinen, G. Ruotolo•September 15, 2020•122 citations
Chat with this paper
Extract insights, manage references, and accelerate your research
Continue your research
– It's free
Abstract
To better understand the marked decrease in serum triglycerides observed with tirzepatide in patients with type 2 diabetes, additional lipoprotein‐related biomarkers were measured post hoc in available samples from the same study.